Treskes M - Search Results

1

Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.

Treskes M, Boven E, van de Loosdrecht AA, Wijffels JF, Cloos J, Peters GJ, Pinedo HM, van der Vijgh WJ. Treskes M, et al. Eur J Cancer. 1994;30A(2):183-7. doi: 10.1016/0959-8049(94)90084-1. Eur J Cancer. 1994. PMID: 8155393

2

Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil.

Peters GJ, van der Wilt CL, Gyergyay F, van Laar JA, Treskes M, van der Vijgh WJ, Pinedo HM. Peters GJ, et al. Among authors: treskes m. Int J Radiat Oncol Biol Phys. 1992;22(4):785-9. doi: 10.1016/0360-3016(92)90524-l. Int J Radiat Oncol Biol Phys. 1992. PMID: 1312075

3

Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.

Treskes M, Boven E, Holwerda U, Pinedo HM, van der Vijgh WJ. Treskes M, et al. Cancer Res. 1992 Apr 15;52(8):2257-60. Cancer Res. 1992. PMID: 1313740

4

The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.

Treskes M, Holwerda U, Nijtmans LG, Pinedo HM, van der Vijgh WJ. Treskes M, et al. Cancer Chemother Pharmacol. 1992;29(6):467-70. doi: 10.1007/BF00684849. Cancer Chemother Pharmacol. 1992. PMID: 1314713

5

Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.

van Laar JA, van der Wilt CL, Treskes M, van der Vijgh WJ, Peters GJ. van Laar JA, et al. Among authors: treskes m. Cancer Chemother Pharmacol. 1992;31(2):97-102. doi: 10.1007/BF00685094. Cancer Chemother Pharmacol. 1992. PMID: 1333372

6

Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.

Treskes M, Nijtmans L, Fichtinger-Schepman AM, van der Vijgh WJ. Treskes M, et al. Anticancer Res. 1992 Nov-Dec;12(6B):2261-5. Anticancer Res. 1992. PMID: 1338281

7

The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.

Treskes M, Holwerda U, Klein I, Pinedo HM, van der Vijgh WJ. Treskes M, et al. Biochem Pharmacol. 1991 Nov 6;42(11):2125-30. doi: 10.1016/0006-2952(91)90347-8. Biochem Pharmacol. 1991. PMID: 1659819

8

WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Treskes M, van der Vijgh WJ. Treskes M, et al. Cancer Chemother Pharmacol. 1993;33(2):93-106. doi: 10.1007/BF00685326. Cancer Chemother Pharmacol. 1993. PMID: 8261581 Review.

9

Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.

Treskes M, Nijtmans LG, Fichtinger-Schepman AM, van der Vijgh WJ. Treskes M, et al. Biochem Pharmacol. 1992 Mar 3;43(5):1013-9. doi: 10.1016/0006-2952(92)90607-k. Biochem Pharmacol. 1992. PMID: 1313234

10

Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines.

Mans DR, Schuurhuis GJ, Treskes M, Lafleur MV, Retèl J, Pinedo HM, Lankelma J. Mans DR, et al. Among authors: treskes m. Eur J Cancer. 1992;28A(8-9):1447-52. doi: 10.1016/0959-8049(92)90541-9. Eur J Cancer. 1992. PMID: 1325177

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters